Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 EX-3.1
- 3.2 EX-3.2
- 10.1 EX-10.1
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.19 EX-10.19
- 10.26 EX-10.26
- 10.31 EX-10.31
- 10.32 EX-10.32
- 16.1 EX-16.1
- 21.1 EX-21.1
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
- Download Excel data file
- View Excel data file
PEARQ similar filings
- 28 Mar 22 Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
- 18 Jan 22 Pear Therapeutics Announces Operational Performance Metrics for Full Year 2021 and Reaffirms Financial and Operational Performance Metrics for Full Year 2022
- 11 Jan 22 Results of Operations and Financial Condition
- 8 Dec 21 Index to Unaudited Condensed Consolidated Financial Statements
- 30 Nov 21 Submission of Matters to a Vote of Security Holders
- 23 Nov 21 Submission of Matters to a Vote of Security Holders
- 22 Nov 21 Other Events
Filing view
External links
Exhibit 16.1
December 7, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by Thimble Point Acquisition Corp. under Item 4.01 of its Form 8-K dated December 7, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Thimble Point Acquisition Corp. contained therein.
Very truly yours,
/s/ Marcum LLP
Marcum LLP n 730 Third Avenue n 11th Floor n New York, New York 10017 n Phone 212.485.5500 n Fax 212.485.5501 n marcumllp.com